Abstract
Proprotein convertase subtilisin-kexin type 9 inhibitor (PCSK9i) has been a game changer in lipid management. Effective and early lipid control has dramatically reduced cardiovascular risk. We report a patient with familial hypercholesterolemia and extensive coronary artery disease, where tight lipid control not only ceased the disease progression, but also resulted in plaque reduction and modification visualized through serial intracoronary imaging.
Recommended Citation
Shek Joyce, Tsui Ping Tim, Breaking the Vicious Cycle: Plaque Regression with the use of PCSK9i in patient with Familial Hypercholesterolemia Journal of the Hong Kong College of Cardiology 2024;31(4) https://doi.org/10.55503/2790-6744.1531
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.